An Observational Study of Treatment for Unresectable Masaoka Stage III/IV and Recurrent Thymoma in Real World

An Observational Study of Treatment for Unresectable Masaoka Stage III/IV and Recurrent Thymoma in Real World - NEJ023B

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000048181

Enrollment

300

Registered

2022-06-27

Start date

2022-06-27

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Unresectable Masaoka III/IV stage and recurrent thymoma

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Histologically diagnosed as thymoma. 2) Diagnosed between 1 April 2000 and 31 March 2020, with stage III or stage IV disease at the time of initial diagnosis and deemed unresectable. Alternatively, recurrence cases between 1 April 2000 and 31 March 2020 after curative surgery. 3) One or more of radiotherapy or anticancer chemotherapy was administered.

Exclusion criteria

Exclusion criteria: None

Design outcomes

Primary

Measure	Time frame
progression-free survival (PFS) and time to treatment failure	—

Secondary

Measure	Time frame
Overall survival, response rate, disease control rate and percentage of cancer genomic profiling tests linked to anticancer chemotherapy.	—

Countries

Japan

Contacts

Public ContactGo Saito / Ryo Ko Go Saito / Ryo Ko

Chiba University / Shizuoka Cancer Center Department of Respirology / Division of Thoracic Oncology

gosaitoh@gmail.com043-222-7171.055-989-5222

Outcome results